The news that was released by Teva today was one of a kind.
If reading the following news carefully – one could deduct that:
laquinimod is the ONLY(!) medicine that could possible reverse(!!) the terrible affects that MS has on the brain(!!!)
Think about that my friends: All the other medicines in the market today could slow down, not stop(!!) the MS disease and its terrible affects on the brain, and surly not reverse its bad affects on the brain(!!!).
Laquinimod on the other hand is the only medicine known today that could possible reverse those terrible affects MS has on the brain(!!!). If true – it would be news of biblical proportions to MS patients and a huge money maker for Teva and its shareholders.
So why am I amazed!!!???
Because even with such possibly great news – the market takes down Teva in an otherwise a very positive day in the market place. So great is the lack of trust that the investment community has in the current management of Teva. :( :( :(
And this is, my friends a terribly amazing thing that goes to show us all what the real problem that Teva suffers from.
"Teva says oral MS drug laquinimod may reduce brain tissue damage
TEL AVIV, Oct 1 (Reuters) - Israel's Teva Pharmaceutical Industries and Sweden's Active Biotech said a Phase III clinical trial of laquinimod, an oral treatment for multiple sclerosis, demonstrated a beneficial impact on brain tissue damage.
The study found that, compared with a placebo, patients treated with laquinimod had decreased rates in brain tissue damage shown by various MRI markers, specifically decreased rates of white matter, grey matter and thalamic atrophy, the companies said on Tuesday.
The patients also developed fewer permanent black holes and accumulated less damage in normal appearing brain tissue."
"These analyses reinforce our faith in the potential of laquinimod," said Michael Hayden, president of global research and development and chief scientific officer for Teva.
He announced plans to initiate a clinical trial of the drug in primary progressive multiple sclerosis.
"We also believe the potential neuroprotective benefits of laquinimod could have significant application in the treatment of other diseases like Crohn's disease, lupus nephritis, Huntington's disease and Alzheimer's," Hayden said."